Open Access Article
Amy C.
Dodds
and
Andrew
Sutherland
*
School of Chemistry, The Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK. E-mail: Andrew.Sutherland@glasgow.ac.uk
First published on 8th February 2022
Phenoxathiins are an important class of sulfur-containing heterocycle, found as the core component in numerous pharmaceutically active agents and materials. Despite this importance, there are relatively few methods for the synthesis of these heterocycles that avoid complex starting materials, harsh conditions or precious transition metals. We report a two-step synthesis of phenoxathiins from phenols using iron and copper-mediated reactions. The first step involves the accelerated ortho-thioarylation of phenols using N-(2-bromophenylthio)succinimide, catalysed by the Lewis acid, iron(III) triflimide and the Lewis base, bis(4-methoxyphenyl)sulfane. In the second step, the thioarylated products were converted to a series of phenoxathiins using a copper-mediated, Ullmann-type, C–O bond forming cyclisation reaction. The synthetic utility of this two-step approach for the preparation of biologically relevant phenoxathiins was demonstrated using natural product-based phenols.
![]() | ||
| Scheme 1 a) Structures of phosphorescent and biologically active phenoxathiins. (b–e) Methods for the synthesis of phenoxathiins. | ||
Despite the interest in phenoxathiin applications, there are relatively few methods for the synthesis of this heterocycle. Traditional methods utilised an aluminium-mediated sulfur insertion reaction of diaryl ethers under harsh conditions (Scheme 1b).9 More recently, several groups reported a two-step approach involving transition metal-mediated thioarylation reactions of phenols as the key step.10 Takaki and co-workers used stoichiometric amounts of iron trichloride and diaryl disulfides as the thioarylating agent (Scheme 1c).10a Palladium catalysed thioarylation using an N-(arylthio)succinimide and trifluoroacetic acid as the solvent has also been utilised.10b Other strategies to access phenoxathiins include a base-mediated coupling and cyclisation of 2-sulfanylphenol with 1,2-dihaloarenes,11 while an approach using N-benzyl dithiocarbamate salts as a sulfur source for copper-catalysed reaction with cyclic diaryliodoniums has also been reported.12 Other single-step processes include the reaction of aryne intermediates with 2-hydroxyaryl 4-toluenethiosulfonates, which allowed the preparation of a wide range of phenoxathiins under mild conditions (Scheme 1d).13
Some of these methods allow the general synthesis of phenoxathiins bearing various substituents and functional groups. However, these methods can require harsh conditions,9,10b highly functionalised starting materials,11–13 stoichiometric amounts of metal reagent10a or the use of precious transition metal catalysts.10b,c In recent years, we have reported the synthesis of various benzannulated heterocycles using earth-abundant, non-precious transition metal catalysts. This approach utilised the super Lewis acid, iron(III) triflimide for the activation of N-halosuccinimides and the regioselective halogenation of arenes, followed by copper-catalysed intramolecular cyclisation to form the heterocycles.14 More recently, we showed that iron(III) triflimide could also be used to activate N-(arylthio)succinimides for the regioselective thioarylation of arenes.15 Based on this work, we proposed that iron(III)-catalysed ortho-thioarylation of para-substituted phenols with N-(2-bromophenylthio)succinimide would generate an intermediate, that following a copper-mediated Ullmann-type cyclisation would allow the rapid synthesis of phenoxathiins. Herein, we now report this two-stage approach for the synthesis of phenoxathiins from phenols. As well as demonstrating the acceleration of the iron-catalysed thioarylation step using the Lewis base catalyst, bis(4-methoxyphenyl)sulfane (Scheme 1e), we also describe the straightforward application of this two-stage approach for the incorporation of the phenoxathiin motif into biologically active compounds.
The scope of the combined Lewis acid and Lewis base-catalysed ortho-thioarylation with a range of phenols was then explored (Scheme 2). For most substrates, the reactions were found to be fast and efficient, and gave biaryl sulfanes in good to high yields. As expected, highly activated compounds (1b and 1d) were thioarylated at lower temperatures, while higher temperatures and longer reaction times (1g) were required for phenols bearing electron-withdrawing substituents. The use of this transformation for bi-directional thioarylation was investigated using hydroquinone (1j) as a starting material. This gave bis-thioarylated product 4j in 79% yield, after a 1 h reaction time. A larger scale reaction was also investigated using 2-naphthol (1f). On a 5 mmol scale, the reaction proceeded as normal, providing gram quantities (1.6 g) of 4f in similar yields to the small-scale reaction (95%).
![]() | ||
Scheme 2 Reaction scope of phenols 1. Isolated yields. a Reaction was done at 40 °C. b Reaction was done at rt. c Reaction was done at 85 °C. d 2.2 equivalents of 2 were used. | ||
Following the effective synthesis of a range of 2-bromobenzene phenol sulfanes 4, these were converted to the corresponding phenoxathiins 5 using a stoichiometric amount of copper(I) thiophene-2-carboxylate under standard conditions for Ullmann-type cyclisation (Scheme 3).10a,b Irrespective of the electronics or steric bulk of the substituents, all cyclisations proceeded efficiently, allowing the synthesis of various phenoxathiins 5 in high yields.18 This reaction also allowed the clean, double-cyclisation of 4j and access to 5,12-dioxa-7,14-dithiapentacene (5j) in 82% yield. A one-pot process that combined the thioarylation and cyclisation steps was also investigated. However, despite testing a range of solvents, the two processes were found to be incompatible due to solubility issues of the starting materials and reagents.
Having developed an efficient two-step synthesis of phenoxathiins using a commercially available Lewis base and earth abundant transition metals, the synthetic utility of this approach for incorporating this heterocyclic motif within biologically active compounds was investigated. Initially, this strategy was used for the synthesis of novel, phenoxathiin-derived α-amino acids (Scheme 4). Application of the Lewis acid and Lewis base catalysed thioarylation of commercially available tyrosine derivative 6 gave biaryl sulfane 7 in 80% yield. It should be noted that an attempt of this transformation using only iron(III) triflimide showed no reaction after 24 h. Cyclisation using copper(I) thiophene-2-carboxylate gave phenoxathiin 8 in 93% yield. Ester hydrolysis, followed by acid-mediated removal of the Cbz-protecting group gave parent α-amino acid 9 in 58% overall yield from tyrosine 6. Diversification of the heterocyclic motif was achieved by oxidation to sulfone 10. Treatment of 8 with hydrogen peroxide in the presence of glacial acetic acid gave sulfone 10 in 95% yield. A similar deprotection strategy gave phenoxathiin-dioxide 11 in 55% yield over the five steps.
A further demonstration of the two-step synthesis of phenoxathiins was applied to the estrogen steroid hormone, estradiol (Scheme 5). While all previous thioarylation reactions gave a single product, application of the optimised method with 17-β-estradiol-17-acetate (12)19 gave two products via reaction at the 2- or 4-ortho positions. Analysis of the crude reaction mixture by 1H NMR spectroscopy showed a 6
:
1 ratio of compounds. The major product, 2-regioisomer 13 was readily separated by flash column chromatography and isolated in 73% yield. Copper(I)-mediated Ullmann-type cyclisation, followed by removal of the acetate protecting group under basic conditions gave steroid-containing phenoxathiin 15 in 52% yield over the three steps.
Based on the results from this study and the control experiments presented in Table 1, a mechanism involving both catalysts has been proposed (Scheme 6). Following formation of iron(III) triflimide from iron(III) chloride and [BMIM]NTf2, the strongly Lewis acidic iron(III) cation activates N-(2-bromophenylthio)succinimide (2).20,21 While this intermediate can undergo slow thioarylation with the phenol, reaction instead with bis(4-methoxyphenyl)sulfane (3) forms a cationic disulfide intermediate. This charged species reacts significantly more quickly with the phenols, forming the ortho-thioarylated products and regenerating the Lewis base catalyst. Evidence of the cationic disuflide or a similarly reactive intermediate was observed from kinetic studies during our previous work of iron(III)-catalysed thioarylation reactions.15 These studies showed that in the absence of a Lewis base, the transformations were autocatalytic with an induction period, requiring the formation of a more reactive intermediate before rate acceleration. Addition of a Lewis base biaryl sulfide showed no induction period, confirming the role of an activated sulfide intermediate in the rate acceleration. Gustafson and co-workers have also proposed cationic disulfide intermediates during their Lewis base and Brønsted acid catalysed thioarylation processes.17
:
1) gave (2-hydroxy-5-methylphenyl)(2′-bromophenyl)sulfane (4a) (69 mg, 81%) as a white solid. Mp 67–69 °C; spectroscopic data was consistent with the literature.10aδH (400 MHz, CDCl3) 2.31 (3H, s, CH3), 6.21 (1H, s, OH), 6.60 (1H, dd, J 8.0, 1.5 Hz, 6′-H), 6.96–7.04 (2H, m, 3-H and 4′-H), 7.09–7.15 (1H, m, 5′-H), 7.23 (1H, dd, J 8.3, 2.0 Hz, 4-H), 7.33 (1H, d, J 2.0 Hz, 6-H), 7.53 (1H, dd, J 7.9, 1.3 Hz, 3′-H); δC (101 MHz, CDCl3) 20.5 (CH3), 114.8 (C), 115.7 (CH), 121.1 (C), 126.8 (CH), 127.0 (CH), 128.2 (CH), 131.2 (C), 133.1 (CH), 133.8 (CH), 137.3 (CH), 137.6 (C), 155.5 (C); m/z (ESI) 319 (MNa+. 100%).
:
3) gave (2-hydroxy-4,5-dimethylphenyl)(2′-bromophenyl)sulfane (4b) (72 mg, 80%) as a white solid. Mp 86–88 °C; νmax/cm−1 (neat) 3446 (OH), 3012 (CH), 1479 (C
C), 1446, 1311, 1204, 1019, 747; δH (400 MHz, CDCl3) 2.21 (3H, s, CH3), 2.29 (3H, s, CH3), 6.13 (1H, s, OH), 6.58 (1H, dd, J 8.0, 1.6 Hz, 6′-H), 6.91 (1H, s, 3-H), 6.96–7.01 (1H, m, 4′-H), 7.07–7.13 (1H, m, 5′-H), 7.26 (1H, s, 6-H), 7.52 (1H, dd, J 7.9, 1.3 Hz, 3′-H); δC (101 MHz, CDCl3) 18.9 (CH3), 20.2 (CH3), 111.4 (C), 116.9 (CH), 120.8 (C), 126.6 (CH), 126.8 (CH), 128.1 (CH), 130.1 (C), 133.0 (CH), 137.5 (CH), 137.9 (C), 142.4 (C), 155.6 (C); m/z (ESI) 330.9763 (MNa+. C14H1379BrNaOS requires 330.9763).
:
1) gave (2-hydroxy-5-t-butylphenyl)(2′-bromophenyl)sulfane (4c) (61 mg, 62%) as a colourless oil. νmax/cm−1 (neat) 3455 (OH), 2959 (CH), 1486 (C
C), 1446, 1181, 1018, 822, 744; δH (400 MHz, CDCl3) 1.32 (9H, s, 3 × CH3), 6.22 (1H, s, OH), 6.57 (1H, dd, J 8.0, 1.5 Hz, 6′-H), 7.01 (1H, td, J 8.0, 1.5 Hz, 4′-H), 7.05 (1H, d, J 8.6 Hz, 3-H), 7.12 (1H, td, J 8.0, 1.5 Hz, 5′-H), 7.47 (1H, dd, J 8.6, 2.5 Hz, 4-H), 7.53 (1H, d, J 2.5 Hz, 6-H), 7.54 (1H, dd, J 8.0, 1.5 Hz, 3′-H); δC (101 MHz, CDCl3) 31.6 (3 × CH3), 34.4 (C), 114.3 (C), 115.5 (CH), 120.9 (C), 126.5 (CH), 126.9 (CH), 128.2 (CH), 130.2 (CH), 133.1 (CH), 134.0 (CH), 137.7 (C), 144.8 (C), 155.4 (C); m/z (ESI) 359.0072 (MNa+. C16H1779BrNaOS requires 359.0076).
:
3) gave [2-hydroxy-4,5-(methylenedioxy)phenyl](2′-bromophenyl)sulfane (4d) (72 mg, 76%) as a white solid. Mp 95–97 °C; νmax/cm−1 (neat) 3397 (OH), 2899 (CH), 1617 (C
C), 1468, 1272, 1181, 1113, 1034, 1016, 935, 856, 760; δH (400 MHz, CDCl3) 5.99 (2H, s, CH2), 6.27 (1H, s, OH), 6.60–6.68 (2H, m, 3-H and 6′-H), 6.92 (1H, s, 6-H), 7.01 (1H, td, J 7.8, 1.6 Hz, 4′-H), 7.11–7.16 (1H, m, 5′-H), 7.52 (1H, dd, J 7.8, 1.3 Hz, 3′-H); δC (101 MHz, CDCl3) 97.9 (CH2), 101.9 (CH), 104.5 (C), 114.7 (CH), 120.8 (C), 126.5 (CH), 127.1 (CH), 128.2 (CH), 133.1 (CH), 137.9 (C), 142.2 (C), 151.6 (C), 154.1 (C); m/z (ESI) 346.9348 (MNa+. C13H979BrNaO3S requires 346.9348).
:
1) gave (2-hydroxy-5-biphenyl)(2′-bromophenyl)sulfane (4e) (79 mg, 76%) as a colourless oil. νmax/cm−1 (neat) 3440 (OH), 3028 (CH), 1504 (C
C), 1472 (C
C), 1285, 1174, 1018, 830, 742; δH (400 MHz, CDCl3) 6.40 (1H, s, OH), 6.68 (1H, dd, J 8.0, 1.6 Hz, 6′′-H), 6.99–7.05 (1H, m, 4′′-H), 7.10–7.16 (1H, m, 5′′-H), 7.19 (1H, d, J 8.5 Hz, 3-H), 7.31–7.36 (1H, m, 4′-H), 7.40–7.46 (2H, m, 3′-H and 5′-H), 7.53–7.60 (3H, m, 2′-H, 6′-H and 3′′-H), 7.68 (1H, dd, J 8.5, 2.3 Hz, 4-H), 7.79 (1H, d, J 2.3 Hz, 6-H); δC (101 MHz, CDCl3) 115.9 (C), 116.4 (CH), 121.3 (C), 126.8 (2 × CH), 127.0 (CH), 127.2 (CH), 127.3 (CH), 128.3 (CH), 129.0 (2 × CH), 131.7 (CH), 133.2 (CH), 135.1 (C), 135.7 (CH), 137.2 (C), 139.7 (C), 157.1 (C); m/z (ESI) 378.9761 (MNa+. C18H1379BrNaOS requires 378.9763).
:
1) gave (2-hydroxynaphthalen-1-yl)(2′-bromophenyl)sulfane (4f) (1.6 g, 95%) as a colourless oil. Spectroscopic data was consistent with the literature.10bδH (400 MHz, CDCl3) 6.32–6.37 (1H, m, 6′-H), 6.92–7.00 (2H, m, 4′-H and 5′-H), 7.02 (1H, s, OH), 7.36 (1H, d, J 8.9 Hz, 3-H), 7.40 (1H, ddd, J 8.1, 6.9, 1.2 Hz, 6-H), 7.51 (1H, ddd, J 8.4, 6.9, 1.3 Hz, 7-H), 7.54–7.59 (1H, m, 3′-H), 7.84 (1H, dd, J 8.1, 1.3 Hz, 5-H), 7.96 (1H, d, J 8.9 Hz, 4-H), 8.15 (1H, dd, J 8.4, 1.2 Hz, 8-H); δC (101 MHz, CDCl3) 107.3 (C), 117.2 (CH), 121.2 (C), 124.2 (CH), 124.7 (CH), 126.5 (CH), 127.0 (CH), 128.1 (CH), 128.4 (CH), 128.8 (CH), 129.7 (C), 133.1 (CH), 133.5 (CH), 135.4 (C), 136.6 (C), 157.4 (C); m/z (ESI) 355 (MNa+. 100%).
:
1) to give 3-(2′-bromophenylthio)-4-hydroxybenzaldehyde (4g) (49 mg, 54%) as an off-white solid. Mp 136–138 °C; νmax/cm−1 (neat) 3207 (OH), 1663 (C
O), 1593 (C
C), 1558, 1488, 1263, 1147, 1018, 745, 719; δH (400 MHz, CDCl3) 6.64 (1H, dd, J 7.9, 1.6 Hz, 6′-H), 7.03–7.08 (2H, m, 4-OH and 4′-H), 7.12–7.16 (1H, m, 5′-H), 7.22 (1H, d, J 8.5 Hz, 5-H), 7.56 (1H, dd, J 7.9, 1.4 Hz, 3′-H), 7.97 (1H, dd, J 8.5, 2.0 Hz, 6-H), 8.08 (1H, d, J 2.0 Hz, 2-H), 9.87 (1H, s, CHO); δC (101 MHz, CDCl3) 116.8 (CH), 117.3 (C), 121.9 (C), 127.5 (CH), 127.9 (CH), 128.4 (CH), 131.0 (C), 133.4 (CH), 134.1 (CH), 136.0 (C), 140.0 (CH), 162.6 (C), 189.9 (CH); m/z (ESI) 330.9397 (MNa+. C13H979BrNaO2S requires 330.9399).
:
1) gave (2-hydroxy-5-chlorophenyl)(2′-bromophenyl)sulfane (4h) (50 mg, 54%) as a white solid. Mp 77–79 °C; νmax/cm−1 (neat) 3391 (OH), 3050 (CH), 1464 (C
C), 1447, 1188, 1017, 817, 740; δH (400 MHz, CDCl3) 6.36 (1H, s, OH), 6.64 (1H, dd, J 7.9, 1.5 Hz, 6′-H), 7.00–7.08 (2H, m, 3-H and 4′-H), 7.15 (1H, td, J 7.9, 1.4 Hz, 5′-H), 7.38 (1H, dd, J 8.8, 2.6 Hz, 4-H), 7.52 (1H, d, J 2.6 Hz, 6-H), 7.55 (1H, dd, J 7.9, 1.4 Hz, 3′-H); δC (101 MHz, CDCl3) 117.1 (C), 117.2 (CH), 121.6 (C), 125.9 (C), 127.2 (CH), 127.6 (CH), 128.4 (CH), 132.9 (CH), 133.3 (CH), 136.2 (CH), 136.4 (C), 156.3 (C); m/z (ESI) 336.9059 (MNa+. C12H879Br35ClNaOS requires 336.9060).
:
1) gave (2-hydroxy-5-fluorophenyl)(2′-bromophenyl)sulfane (4i) (30 mg, 34%) as a colourless oil. νmax/cm−1 (neat) 3437 (OH), 3061 (CH), 1478 (C
C), 1445, 1194, 1017, 818, 770, 743; δH (400 MHz, CDCl3) 6.20 (1H, s, OH), 6.66 (1H, dd, J 8.0, 1.5 Hz, 6′-H), 7.01–7.08 (2H, m, 3-H and 4′-H), 7.11–7.17 (2H, m, 6-H and 5′-H), 7.22–7.27 (1H, m, 4-H), 7.55 (1H, dd, J 7.9, 1.4 Hz, 3′-H); δC (101 MHz, CDCl3) 116.3 (d, 3JCF 8.3 Hz, C), 116.8 (d, 3JCF 7.9 Hz, CH), 119.9 (d, 2JCF 23.0 Hz, CH), 121.7 (C), 122.7 (d, 2JCF 23.1 Hz, CH), 127.3 (CH), 127.6 (CH), 128.3 (CH), 133.3 (CH), 136.5 (C), 154.0 (d, 4JCF 2.4 Hz, C), 156.7 (d, 1JCF 242.1 Hz, C); m/z (ESI) 296.9392 ([M − H]−. C12H779BrFOS requires 296.9391).
:
2) to give 1,4-bis-[(2′-bromophenyl)sulfane]-2,5-dihydroxybenzene (4j) (121 mg, 79%) as a white solid. Mp 189–190 °C; νmax/cm−1 (neat) 3414 (OH), 3056 (CH), 1458 (C
C), 1443, 1302, 1189, 1018, 798, 739; δH (400 MHz, CDCl3) 5.98 (2H, s, 2 × OH), 6.81 (2H, dd, J 7.8, 1.5 Hz, 2 × 6′-H), 7.07 (2H, td, J 7.8, 1.5 Hz, 2 × 4′-H), 7.19 (2H, td, J 7.8, 1.5 Hz, 2 × 5′-H), 7.24 (2H, s, 3-H and 6-H), 7.57 (2H, dd, J 7.8, 1.5 Hz, 2 × 3′-H); δC (101 MHz, CDCl3) 120.6 (2 × C), 122.3 (2 × C), 122.5 (2 × CH), 127.9 (2 × CH), 128.1 (2 × CH), 128.4 (2 × CH), 133.4 (2 × CH), 136.1 (2 × C), 151.1 (2 × C); m/z (ESI) 482.8698 (MH+. C18H1379Br2O2S2 requires 482.8718).
C), 1441, 1218, 1023, 874, 756; δH (400 MHz, CDCl3) 2.17 (3H, s, CH3), 2.20 (3H, s, CH3), 6.81 (1H, s, 4-H), 6.85 (1H, s, 1-H), 6.95–7.01 (2H, m, 6-H and 8-H), 7.06–7.13 (2H, m, 7-H and 9-H); δC (101 MHz, CDCl3) 19.0 (CH3), 19.6 (CH3), 116.2 (C), 117.8 (CH), 118.9 (CH), 120.6 (C), 124.3 (CH), 126.9 (CH), 127.4 (CH), 127.6 (CH), 132.9 (C), 136.4 (C), 150.1 (C), 152.5 (C); m/z (ESI) 251.0502 (MNa+. C14H12NaOS requires 251.0501).
C), 1442, 1262, 1227, 853, 750; δH (400 MHz, CDCl3) 1.29 (9H, s, 3 × CH3), 6.95 (1H, d, J 8.4 Hz, 4-H), 6.97–7.02 (2H, m, 6-H and 8-H), 7.09–7.16 (4H, m, 1-H, 3-H, 7-H and 9-H); δC (101 MHz, CDCl3) 31.5 (3 × CH3), 34.5 (C), 117.3 (CH), 117.9 (CH), 119.4 (C), 120.4 (C), 123.8 (CH), 124.5 (CH), 124.9 (CH), 126.9 (CH), 127.7 (CH), 147.8 (C), 150.0 (C), 152.5 (C); m/z (ESI) 279.0815 (MNa+. C16H16NaOS requires 279.0814).
:
1) gave 2,3-(methylenedioxy)phenoxathiin (5d) (38 mg, 93%) as a colourless oil. νmax/cm−1 (neat) 2888 (CH), 1459 (C
C), 1219, 1118, 1032, 933, 850, 746; δH (400 MHz, CDCl3) 5.94 (2H, s, CH2), 6.57 (1H, s, 4-H), 6.62 (1H, s, 1-H), 6.98–7.04 (2H, m, 6-H and 8-H), 7.10–7.16 (2H, m, 7-H and 9-H); δC (101 MHz, CDCl3) 100.6 (CH), 101.8 (CH2), 106.2 (CH), 111.4 (C), 117.8 (CH), 121.0 (C), 124.7 (CH), 126.9 (CH), 127.9 (CH), 144.6 (C), 147.4 (C), 147.5 (C), 152.9 (C); m/z (ESI) 267.0087 (MNa+. C13H8NaO3S requires 267.0086).
C), 1439 (C
C), 1262, 1210, 1077, 938, 745; δH (400 MHz, CDCl3) 6.98–7.05 (2H, m, 6-H and 8-H), 7.07 (1H, d, J 8.3 Hz, 4-H), 7.10–7.18 (2H, m, 7-H and 9-H), 7.29–7.39 (3H, m, 1-H, 3-H and 4′-H), 7.40–7.47 (2H, m, 3′-H and 5′-H), 7.50–7.56 (2H, m, 2′-H and 6′-H); δC (101 MHz, CDCl3) 117.9 (CH), 118.1 (CH), 119.9 (C), 120.5 (C), 124.7 (CH), 125.4 (CH), 126.6 (CH), 126.9 (2 × CH), 127.0 (CH), 127.5 (CH), 127.9 (CH), 129.0 (2 × CH), 138.0 (C), 139.9 (C), 151.6 (C), 152.2 (C); m/z (ESI) 299.0501 (MNa+. C18H12NaOS requires 299.0501).
:
3) gave 2-formylphenoxathiin (5g) (36 mg, 92%) as a yellow solid. Mp 82–83 °C; νmax/cm−1 (neat) 2727 (CH), 1683 (C
O), 1592 (C
C), 1466, 1238, 1198, 1080, 810, 752; δH (400 MHz, CDCl3) 6.97–7.08 (4H, m, 4-H, 6-H, 8-H and 9-H), 7.14 (1H, ddd, J 8.0, 6.9, 2.1 Hz, 7-H), 7.59 (1H, d, J 2.0 Hz, 1-H), 7.62 (1H, dd, J 8.3, 2.0 Hz, 3-H), 9.84 (1H, s, CHO); δC (101 MHz, CDCl3) 118.0 (CH), 118.3 (CH), 118.6 (C), 121.4 (C), 125.4 (CH), 126.9 (CH), 128.1 (CH), 128.2 (CH), 130.2 (CH), 133.3 (C), 150.9 (C), 156.6 (C), 190.1 (CH); m/z (ESI) 251.0136 (MNa+. C13H8NaO2S requires 251.0137).
C), 1439, 1377, 1285, 1261, 1099, 799, 737; δH (400 MHz, CDCl3) 6.89–6.94 (1H, m, 6-H), 6.96–7.10 (5H, m, 1-H, 3-H, 4-H, 8-H and 9-H), 7.14 (1H, ddd, J 7.9, 7.4, 1.8 Hz, 7-H); δC (101 MHz, CDCl3) 118.0 (CH), 118.8 (CH), 119.2 (C), 122.2 (C), 124.9 (CH), 126.4 (CH), 126.9 (CH), 127.7 (CH), 128.1 (CH), 129.5 (C), 150.9 (C), 152.0 (C); m/z (ESI) 234.9958 (MH+. C12H835ClOS requires 234.9979).
C), 1442, 1245, 1183, 853, 753; δH (400 MHz, CDCl3) 6.78–6.85 (2H, m, 1-H and 3-H), 6.95 (1H, ddd, J 8.5, 4.8, 0.7 Hz, 4-H), 6.99–7.04 (2H, m, 6-H and 8-H), 7.09 (1H, dd, J 7.7, 1.7 Hz, 9-H), 7.12–7.17 (1H, m, 7-H); δC (101 MHz, CDCl3) 113.5 (d, 2JCF 26.0 Hz, CH), 114.3 (d, 2JCF 23.3 Hz, CH), 118.0 (CH), 118.7 (d, 3JCF 8.6 Hz, CH), 119.3 (C), 122.1 (d, 3JCF 8.9 Hz, C), 124.8 (CH), 126.9 (CH), 128.1 (CH), 148.4 (d, 4JCF 2.7 Hz, C), 152.3 (C), 159.3 (d, 1JCF 243.9 Hz, C); m/z (ESI) 236.0529 (MNH4+. C12H11FNOS requires 236.0540).
:
1) gave 5,12-dioxa-7,14-dithiapentacene (5j) (49 mg, 82%) as a white solid. Mp 216–218 °C; νmax/cm−1 (neat) 3070 (CH), 1450 (C
C), 1439, 1370, 1261, 1205, 1169, 874, 747; δH (400 MHz, CDCl3) 6.77 (2H, s, 6-H and 13-H), 6.95–7.03 (4H, m, 2 × 2-H and 2 × 4-H), 7.07–7.15 (4H, m, 2 × 1-H and 2 × 3-H); δC (101 MHz, CDCl3) 115.5 (2 × CH), 118.0 (2 × CH), 119.3 (2 × C), 119.5 (2 × C), 124.8 (2 × CH), 126.9 (2 × CH), 128.1 (2 × CH), 148.7 (2 × C), 152.1 (2 × C); m/z (ESI) 340.0465 ([MNH4]+. C18H14NO2S2 requires 340.0460).
C), 1446, 1216, 1019, 757; [α]D25 +42.7 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 3.01 (1H, dd, J 14.0, 5.8 Hz, 3-HH), 3.11 (1H, dd, J 14.0, 5.5 Hz, 3-HH), 3.67 (3H, s, CO2CH3), 4.63 (1H, ddd, J 8.0, 5.8, 5.5 Hz, 2-H), 5.07 (1H, d, J 12.2 Hz, PhCHH), 5.10 (1H, d, J 12.2 Hz, PhCHH), 5.29 (1H, d, J 8.0 Hz, NH), 6.36 (1H, s, OH), 6.53 (1H, dd, J 8.0, 1.5 Hz, 6′′-H), 6.95–7.03 (2H, m, 5′-H and 4′′-H), 7.05–7.12 (1H, m, 5′′-H), 7.15 (1H, dd, J 8.4, 2.2 Hz, 6′-H), 7.28–7.39 (6H, m, 2′-H and Ph), 7.52 (1H, dd, J 7.9, 1.3 Hz, 3′′-H); δC (101 MHz, CDCl3) 37.4 (CH2), 52.6 (CH3), 55.0 (CH), 67.2 (CH2), 115.4 (C), 116.2 (CH), 121.1 (C), 126.8 (CH), 127.1 (CH), 128.2 (2 × CH), 128.3 (CH), 128.4 (CH), 128.7 (2 × CH), 129.2 (C), 133.1 (CH), 133.9 (CH), 136.3 (C), 137.3 (C), 137.9 (CH) 155.6 (C), 156.8 (C), 171.8 (C); m/z (ESI) 538.0288 (MNa+. C24H2279BrNNaO5S requires 538.0294).
C), 1464, 1442, 1230, 1206, 1056, 747; [α]D25 +48.7 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 2.98 (1H, dd, J 14.0, 6.0 Hz, 3-HH), 3.06 (1H, dd, J 14.0, 5.6 Hz, 3-HH), 3.73 (3H, s, CO2CH3), 4.62 (1H, ddd, J 8.0, 6.0, 5.6 Hz, 2-H), 5.08 (1H, d, J 12.2 Hz, PhCHH), 5.13 (1H, d, J 12.2 Hz, PhCHH), 5.23 (1H, d, J 8.0 Hz, NH), 6.81–6.85 (2H, m, 1′-H and 4′-H), 6.87–6.91 (1H, m, 3′-H), 6.97–7.02 (2H, m, 6′-H and 8′-H), 7.08 (1H, dd, J 7.7, 1.5 Hz, 9′-H), 7.10–7.14 (1H, m, 7′-H), 7.29–7.38 (5H, m, Ph); δC (101 MHz, CDCl3) 37.5 (CH2), 52.6 (CH3), 54.9 (CH), 67.2 (CH2), 117.9 (CH), 118.0 (CH), 119.9 (C), 120.5 (C), 124.7 (CH), 126.9 (CH), 127.5 (CH), 127.9 (CH), 128.2 (2 × CH), 128.4 (CH), 128.7 (CH), 128.7 (2 × CH), 132.3 (C), 136.3 (C), 151.4 (C), 152.2 (C), 155.7 (C) 171.9 (C); m/z (ESI) 458.1031 (MNa+. C24H21NNaO5S requires 458.1033).
C), 1265, 1231, 1053, 748; [α]D20 +7.1 (c 0.1, MeOH); δH (400 MHz, CD3OD) 2.84 (1H, dd, J 14.0, 9.4 Hz, 3-HH), 3.13 (1H, dd, J 14.0, 4.8 Hz, 3-HH), 4.39 (1H, dd, J 9.4, 4.8 Hz, 2-H), 4.98 (1H, d, J 12.5 Hz, PhCHH), 5.06 (1H, d, J 12.5 Hz, PhCHH), 6.88 (1H, d, J 8.2 Hz, 6′-H), 6.96–7.06 (4H, m, 1′-H, 4′-H, 8′-H and 9′-H), 7.10 (1H, dd, J 7.7, 1.5 Hz, 3′-H), 7.12–7.31 (5H, m, 7′-H and Ph); δC (101 MHz, CD3OD) 37.8 (CH2), 56.7 (CH), 67.5 (CH2), 118.5 (CH), 118.7 (CH), 121.1 (C), 121.3 (C), 125.7 (CH), 127.8 (CH), 128.5 (CH), 128.6 (2 × CH), 128.9 (CH), 129.0 (CH), 129.4 (2 × CH), 129.9 (CH), 135.4 (C), 138.2 (C), 152.3 (C), 153.5 (C), 158.4 (C), 175.0 (C); m/z (ESI) 422.1060 (MH+. C23H20NO5S requires 422.1057).
C), 1439, 1265, 1200, 1123, 741; [α]D21 −3.1 (c 0.1, MeOH); δH (400 MHz, CD3OD) 3.09 (1H, dd, J 14.6, 7.7 Hz, 3-HH), 3.25 (1H, dd, J 14.6, 5.5 Hz, 3-HH), 4.22 (1H, dd, J 7.7, 5.5 Hz, 2-H), 6.99–7.20 (7H, m, 1′-H, 3′-H, 4′-H, 6′-H, 7′-H, 8′-H and 9′-H); δC (101 MHz, CD3OD) 36.4 (CH2), 55.0 (CH), 118.7 (CH), 119.2 (CH), 120.9 (C), 122.2 (C), 126.0 (CH), 127.9 (CH), 128.8 (CH), 129.2 (CH), 130.1 (CH), 132.3 (C), 153.2 (C), 153.4 (C), 171.2 (C); m/z (ESI) 288.0690 (MH+. C15H14NO3S requires 288.0689).
:
1) gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10′,10′-dioxide-2′-yl)propanoate (10) (62.0 mg, 75%) as a white solid. Mp 122–124 °C; νmax/cm−1 (neat) 3348 (NH), 2954 (CH), 1714 (CO), 1520 (C
C), 1469, 1273, 1152, 1063, 757; [α]D25 +65.9 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 3.15 (1H, dd, J 14.0, 6.2 Hz, 3-HH), 3.26 (1H, dd, J 14.0, 5.4 Hz, 3-HH), 3.75 (3H, s, CO2CH3), 4.67 (1H, ddd, J 7.6, 6.2, 5.4 Hz, 2-H), 5.10 (2H, s, PhCH2), 5.42 (1H, d, J 7.6 Hz, NH), 7.26–7.43 (9H, m, 3′-H, 4′-H, 6′-H, 8′-H and Ph), 7.61–7.67 (1H, m, 7′-H), 7.79 (1H, d, J 1.9 Hz, 1′-H), 8.04 (1H, dd, J 7.9, 1.2 Hz, 9′-H); δC (101 MHz, CDCl3) 37.7 (CH2), 52.8 (CH3), 54.8 (CH), 67.2 (CH2), 119.0 (CH), 119.2 (CH), 123.5 (CH), 123.8 (CH), 124.9 (C), 124.9 (C), 125.0 (CH), 128.2 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 133.4 (C), 134.3 (CH), 135.2 (CH), 136.2 (C), 150.6 (C), 151.6 (C), 155.7 (C), 171.4 (C); m/z (ESI) 490.0931 (MNa+. C24H21NNaO7S requires 490.0931).
C), 1273, 1150, 1062, 750; [α]D24 +13.8 (c 0.1, MeOH); δH (500 MHz, CD3OD) 3.05 (1H, dd, J 14.0, 9.6 Hz, 3-HH), 3.34 (1H, dd, J 14.0, 4.4 Hz, 3-HH), 4.48 (1H, dd, J 9.6, 4.4 Hz, 2-H), 4.97 (1H, d, J 12.5 Hz, PhCHH), 5.02 (1H, d, J 12.5 Hz, PhCHH), 7.13–7.29 (5H, m, Ph), 7.34 (1H, d, J 8.5 Hz, 4′-H), 7.43–7.48 (2H, m, 6′-H and 8′-H), 7.59 (1H, dd, J 8.5, 1.9 Hz, 3′-H), 7.72 (1H, t, J 7.8 Hz, 7′-H), 7.89 (1H, d, J 1.9 Hz, 1′-H), 8.00 (1H, d, J 8.1 Hz, 9′-H); δC (126 MHz, CD3OD) 37.8 (CH2), 56.5 (CH), 67.6 (CH2), 120.1 (CH), 120.2 (CH), 124.1 (CH), 124.4 (CH), 125.9 (C), 126.2 (CH), 126.3 (C), 128.7 (2 × CH), 128.8 (CH), 129.4 (2 × CH), 135.7 (CH), 136.5 (C), 136.7 (CH), 138.1 (C), 151.8 (C), 153.0 (C), 158.4 (C) 174.6 (C); m/z (ESI) 476.0776 (MNa+. C23H19NNaO7S requires 476.0774).
C), 1471, 1272, 1199, 1148, 758; [α]D24 +30.3 (c 0.1, MeOH); δH (500 MHz, CD3OD) 3.34 (1H, dd, J 14.7, 7.4 Hz, 3-HH), 3.45 (1H, dd, J 14.7, 5.9 Hz, 3-HH), 4.37 (1H, dd, J 7.4, 5.9 Hz, 2-H), 7.49–7.55 (3H, m, 4′-H, 6′-H and 8′-H), 7.72 (1H, dd, J 8.6, 1.5 Hz, 3′-H), 7.78 (1H, t, J 7.9 Hz, 7′-H), 7.99 (1H, d, J 1.5 Hz, 1′-H), 8.03 (1H, d, J 7.9 Hz, 9′-H); δC (126 MHz, CD3OD) 36.4 (CH2), 54.7 (CH), 120.2 (CH), 120.9 (CH), 124.1 (CH), 125.0 (CH), 126.3 (C), 126.4 (CH), 126.5 (C) 133.4 (C), 135.9 (CH), 136.9 (CH), 152.6 (C), 152.9 (C), 170.9 (C); m/z (ESI) 342.0405 (MNa+. C15H13NNaO5S requires 342.0407).
:
2) gave 2-(2′-bromophenylthio)-17-β-estradiol-17-acetate (13) (107 mg, 73%) as a white solid. Mp 172–175 °C; νmax/cm−1 (neat) 3406 (OH), 2924 (CH), 1724 (CO), 1481 (C
C), 1427, 1346, 1015, 891, 745; [α]D20 +48.7 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 0.84 (3H, s, 13-CH3), 1.21–1.61 (7H, m, 7-H2, 8-H, 11-HH, 15-H2 and 16-HH), 1.70–1.81 (1H, m, 9-H), 1.84–1.94 (2H, m, 11-HH and 14-H), 2.05 (3H, s, COCH3), 2.16–2.28 (3H, m, 12-H2 and 16-HH), 2.86–2.92 (2H, m, 6-H2), 4.68 (1H, dd, J 9.0, 8.0 Hz, 17-H), 6.13 (1H, s, OH), 6.59 (1H, dd, J 7.8, 1.5 Hz, 6′-H), 6.82 (1H, s, 4-H), 6.99 (1H, td, J 7.8, 1.5 Hz, 4′-H), 7.11 (1H, td, J 7.8, 1.3 Hz, 5′-H), 7.41 (1H, s, 1-H), 7.52 (1H, dd, J 7.8, 1.3 Hz, 3′-H); δC (101 MHz, CDCl3) 12.2 (CH3), 21.3 (CH3), 23.4 (CH2), 26.3 (CH2), 27.1 (CH2), 27.7 (CH2), 29.8 (CH2), 36.9 (CH2), 38.4 (CH), 43.0 (C), 43.8 (CH), 49.9 (CH), 82.8 (CH), 112.0 (C), 115.7 (CH), 120.8 (C), 126.6 (CH), 126.8 (CH), 128.1 (CH), 133.0 (CH), 134.2 (CH), 134.3 (C), 138.0 (C), 142.6 (C), 155.3 (C), 171.4 (C); m/z (ESI) 501.1091 (MH+. C26H3079BrO3S requires 501.1090).
:
3) gave (15S,18S,19S,22S,23R)-18-methyl-4-oxa-11-thiahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-yl acetate (14) (32 mg, 76%) as a white solid. Mp 185–187 °C; νmax/cm−1 (neat) 2928 (CH), 1724 (C
O), 1462 (C
C), 1288, 1037, 879, 752; [α]D21 +44.9 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 0.82 (3H, s, 18-CH3), 1.21–1.56 (7H, m, 16-HH, 20-HH, 21-H2, 23-H and 24-H2), 1.69–1.77 (1H, m, 15-H), 1.82–1.91 (2H, m, 16-HH and 22-H), 2.06 (3H, s, COCH3), 2.09–2.28 (3H, m, 17-H2 and 20-HH), 2.76–2.82 (2H, m, 25-H2), 4.68 (1H, dd, J 9.1, 7.9 Hz, 19-H), 6.73 (1H, s, 2-H), 6.87–7.00 (3H, m, 6-H, 8-H and 13-H), 7.05–7.13 (2H, m, 7-H and 9-H); δC (101 MHz, CDCl3) 12.2 (CH3), 21.3 (CH3), 23.4 (CH2), 26.3 (CH2) 27.1 (CH2), 27.7 (CH2), 29.3 (CH2), 36.9 (CH2), 38.4 (CH), 43.0 (C), 43.9 (CH), 49.9 (CH), 82.8 (CH), 116.6 (C), 117.7 (CH), 117.8 (CH), 120.6 (C), 123.7 (CH), 124.4 (CH), 126.9 (CH), 127.6 (CH), 136.8 (C), 136.9 (C), 150.0 (C), 152.4 (C), 171.3 (C); m/z (ESI) 443.1651 (MNa+. C26H28NaO3S requires 443.1651).
:
3) gave (15S,18S,19S,22S,23R)-18-methyl-4-oxa-11-thiahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-ol (15) (14 mg, 93%) as a white solid. Mp 197–199 °C; νmax/cm−1 (neat), 3565 (OH), 2905 (CH), 1466 (C
C), 1443, 1215, 1065, 860, 745; [α]D21 +89.1 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 0.77 (3H, s, 18-CH3), 1.10–1.55 (8H, m, OH, 16-HH, 20-HH, 21-H2, 23-H and 24-H2), 1.65 (1H, m, 15-H), 1.83–1.90 (1H, m, 16-HH), 1.92–1.97 (1H, m, 22-H), 2.06–2.17 (2H, m, 17-H2), 2.22–2.29 (1H, m, 20-HH), 2.76–2.82 (2H, m, 25-H2), 3.72 (1H, t, J 8.4 Hz, 19-H), 6.74 (1H, s, 2-H), 6.93–7.01 (3H, m, 6-H, 8-H and 13-H), 7.07–7.12 (2H, m, 7-H and 9-H); δC (101 MHz, CDCl3) 11.2 (CH3), 23.3 (CH2), 26.4 (CH2), 27.2 (CH2), 29.3 (CH2), 30.7 (CH2), 36.7 (CH2), 38.7 (CH), 43.3 (C), 44.0 (CH), 50.1 (CH), 82.0 (CH), 116.6 (C), 117.7 (CH), 117.8 (CH), 120.6 (C), 123.7 (CH), 124.4 (CH), 126.9 (CH), 127.6 (CH), 136.9 (C), 137.1 (C), 150.0 (C), 152.4 (C); m/z (ESI) 401.1532 (MNa+. C24H26NaO2S requires 401.1546).
Footnote |
| † Electronic supplementary information (ESI) available: 1H and 13C NMR spectra for all compounds. See DOI: 10.1039/d2ob00022a |
| This journal is © The Royal Society of Chemistry 2022 |